全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Progressive Symmetrical Erythrokeratoderma-Like Psoriasis: A New Case Report

DOI: 10.4236/jcdsa.2021.114024, PP. 293-303

Keywords: Progressive Symmetrical Erythrokeratoderma, Psoriasis, Down Syndrome, Pruritus, Biological Therapy, Hyperpigmentation

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Psoriasis, a chronic, systemic, inflammatory disease with prominent skin involvement, affects approximately 2% - 4% of the world population. Common variants of psoriasis are plaque psoriasis, inverse psoriasis, guttate psoriasis, erythrodermic psoriasis, pustular form either palmoplantar pustular psoriasis or generalized pustular psoriasis, nail psoriasis, and psoriatic arthritis. Progressive Symmetrical Erythrokeratoderma (PSEK) is a rare genetic disorder, characterized by fixed, well-defined erythematous and hyperkeratotic plaques distributed predominantly on the elbows, knees, trunk, and dorsal surfaces of hands and feet. Clinically has the same presentation to psoriasis especially at early onset and could be confused with psoriasis but histopathological findings and progression of the psoriatic disease can differentiate between both conditions. Aim: To document a new variant of a severe, recalcitrant type of psoriasis with a history of recurrent attacks of exacerbations and partial remissions especially in lesions involving lower extremities that are clinically PSEK-like in presentation, but histopathologically consistent with psoriasis. Case report: A 12-year-old childhood male, known case of Down’s syndrome, presented to our clinic with a history of severely pruritic skin rashes involving the perioral area, corners of the mouth, bilateral elbows, dorsal hands, scrotum, and both lower extremities for 6 years duration. The rashes gradually progressed with time to form fixed lesions in the last 2 years. He was received multiple treatment modalities, including topical steroids, topical vitamin D derivatives, and narrowband UVB phototherapy without significant improvement and the lesions became more worsened over time. Conclusion: psoriasis can be presenting with a new variant of a severe, recalcitrant, and difficult to treat type in Down syndrome cases with a history of recurrent attacks of exacerbations and partial remissions especially in lesions involving lower extremities which are clinically PSEK-like in presentation, but histopathologically consistent with psoriasis. However, early diagnosis and strict management are important in controlling the severity of the condition.

References

[1]  Rachakonda, T.D., Schupp, C.W. and Armstrong, A.W. (2014) Psoriasis Prevalence among Adults in the United States. Journal of the American Academy of Dermatology, 70, 512-516. https://doi.org/10.1016/j.jaad.2013.11.013
[2]  Parisi, R., Symmons, D.P.M., Griffiths, C.E.M. and Ashcroft, D.M. (2013) Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology, 133, 377-385. https://doi.org/10.1038/jid.2012.339
[3]  Rapp, S.R., Feldman, S.R., Exum, M.L., Fleischer, A.B. and Reboussin, D.M. (1999) Psoriasis Causes as Much Disability as Other Major Medical Diseases. Journal of the American Academy of Dermatology, 41, 401-407.
https://doi.org/10.1016/S0190-9622(99)70112-X
[4]  Wu, Y., Mills, D. and Bala, M. (2009) Impact of Psoriasis on Patients’ Work and Productivity: A Retrospective, Matched Case-Control Analysis. American Journal of Clinical Dermatology, 10, 407-410.
https://doi.org/10.2165/11310440-000000000-00000
[5]  Kimball, A.B., Jacobson, C., Weiss, S., Vreeland, M.G. and Wu, Y. (2005) The Psychosocial Burden of Psoriasis. American Journal of Clinical Dermatology, 6, 383-392.
https://doi.org/10.2165/00128071-200506060-00005
[6]  Reich, K., Armstrong, A.W., Langley, R.G., Flavin, S., Randazzo, B., Li, S. and Blauvelt, A. (2019) Guselkumab versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results from a Phase 3, Randomized Controlled Trial. The Lancet, 394, 831-839.
https://doi.org/10.1016/S0140-6736(19)31773-8
[7]  Langley, R.G.B., Krueger, G.G. and Griffiths, C.E.M. (2005) Psoriasis: Epidemiology, Clinical Features, and Quality of Life. Annals of the Rheumatic Diseases, 64, ii18-ii23. https://doi.org/10.1136/ard.2004.033217
[8]  Ladizinski, B., Lee, K.C., Wilmer, E., Alavi, A., Mistry, N. and Sibbald, R.G. (2013) A Review of the Clinical Variants and the Management of Psoriasis. Advances in Skin & Wound Care, 26, 271-284.
https://doi.org/10.1097/01.ASW.0000429778.10020.67
[9]  Brandon, A., Mufti, A. and Gary Sibbald, R. (2019) Diagnosis and Management of Cutaneous Psoriasis: A Review. Advances in Skin & Wound Care, 32, 58-69.
https://doi.org/10.1097/01.ASW.0000550592.08674.43
[10]  Darier, J. (1911) Progressive Symmetric Erythrokeratodermia Verrucosa. Bulletin de la Société Française de Dermatologie et de Syphiligraphie, 22, 252-264
[11]  Gottron, H.A. (1923) Congenital Symmetrical Progressive Erythrokeratoderma. Archives of Dermatology, 7, 416.
[12]  Khoo, B.P., Tay, Y.K. and Tan, S.H. (2000) Generalized Erythematous Plaques. Progressive Symmetric Erythrokeratoderma (PSEK) (Erythrokeratodermia Progressive Symmetrical). Archives of Dermatology, 136, 665-668.
[13]  de Mello Guaraldi, B., Jaime, T.J., de Mello Guaraldi, R., Melo, D.F., Nogueira, O.M. and Rodrigues, N. (2013) Progressive Symmetrical Erythrokeratodermia—Case Report. Anais Brasileiros de Dermatologia, 88, 109-112.
https://doi.org/10.1590/S0365-05962013000100016
[14]  Raychaudhuri, S.P. and Gross, J. (2000) A Comparative Study of Pediatric-Onset Psoriasis with Adult-Onset Psoriasis. Pediatric Dermatology, 17, 174-178.
https://doi.org/10.1046/j.1525-1470.2000.01746.x
[15]  Catarina, A., Resende, C., Vieira, A.P., Fernandes, J.C. and Brito, C. (2015) Plaque Psoriasis in a Patient with Down Syndrome—Potential Common Pathophysiology and Treatment Difficulty. Journal of the Portuguese Society of Dermatology and Venereology, 73, 147-150. https://doi.org/10.29021/spdv.73.1.357
[16]  Marmon, S., De Souza, A. and Strober, B.E. (2012) Psoriasis and Down Syndrome: A Report of Three Cases and a Potential Pathophysiologic Link. Dermatology Online Journal, 18, 13. https://doi.org/10.5070/D305M5F4BX
[17]  Ram, G. and Chinen, J. (2011) Infections and Immunodeficiency in Down Syndrome. Clinical & Experimental Immunology, 164, 9-16.
https://doi.org/10.1111/j.1365-2249.2011.04335.x
[18]  Murphy, M., Insoft, R.M., Pike-Nobile, L. and Epstein, L.B. (1995) A Hypothesis to Explain the Immune Defects in Down Syndrome. Progress in Clinical and Biological Research, 393, 147-167.
[19]  Szepietowski, J.C. and Reich, A. (2016) Pruritus in Psoriasis: An Update. European Journal of Pain, 20, 41-46. https://doi.org/10.1002/ejp.768
[20]  Amatya, B., Wennersten, G. and Nordlind, K. (2008) Patients’ Perspective of Pruritus in Chronic Plaque Psoriasis: A Questionnaire-Based Study. Journal of the European Academy of Dermatology and Venereology, 22, 822-826.
https://doi.org/10.1111/j.1468-3083.2008.02591.x
[21]  Shahwan, K.T. and Kimball, A.B. (2017) Itch Intensity in Moderate-to-Severe Plaque Psoriasis versus Atopic Dermatitis: A Meta-Analysis. Journal of the American Academy of Dermatology, 76, 1198-1200. https://doi.org/10.1016/j.jaad.2017.02.002
[22]  Wang, C.Q.F., Akalu, Y.T., Suarez-Farinas, M., et al. (2013) IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis. Journal of Investigative Dermatology, 133, 2741-2752.
https://doi.org/10.1038/jid.2013.237
[23]  Santa María, P., Valenzuela, F., Morales, C., De la Fuente, R. and Cullen, R. (2017) Lentiginous Eruption in Resolving Psoriasis Plaques during Treatment with Ixekizumab: A Case Report and Review of the Literature. Dermatology Reports, 9, Article ID: 7079. https://doi.org/10.4081/dr.2017.7079
[24]  Woronoff, D.L. (1926) Die peripheren Veränderungen der Haut um die Effloreszenzen der Psoriasis vulgaris und Syphilis corymbosa. Dermatologische Wochenschrift, 82, 249-257.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133